J. Goldman & Co LP

Position in ANNX — Annexon, Inc.

CIK 1412741 NEW YORK, NY

Back to ANNX Full portfolio

Position in ANNX

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$946,326

-$4,042,524 QoQ

Shares Held

170,817

-82.8% QoQ

Ownership

0.086%

of shares outstanding

% of Portfolio

0.05%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2024

5 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in ANNX Over Time

Shares Held

Position Value (USD)

Derivatives in ANNX

reported options exposure · as of Jun 30, 2024

CallValue

$793,800

CallShares

162,000

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

J. Goldman & Co LP holds $186,196,918 across 52 Biotechnology names. ANNX ranks #32 (0.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	COGT	Cogent Biosciences, Inc.	779,570	$30,005,649
2	ARDX	Ardelyx, Inc.	3,000,513	$17,973,072
3	IONS	Ionis Pharmaceuticals Inc	235,260	$17,665,673
4	URGN	UroGen Pharma Ltd.	938,870	$16,880,882
5	CAPR	Capricor Therapeutics, Inc.	541,522	$16,462,268
6	REGN	Regeneron Pharmaceuticals, Inc.	16,268	$12,569,307
7	VSTM	Verastem, Inc.	1,680,752	$8,907,985
8	PRAX	Praxis Precision Medicines, Inc.	15,664	$5,046,784

All Filings in ANNX

Export CSV

5 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$946,326	170,817	-82.8%	Shares	Sole	2026-05-15
2025-12-31	$4,988,850	993,795	-10.2%	Shares	Sole	2026-02-17
2025-09-30	$3,376,353	1,107,001	+583.3%	Shares	Sole	2025-11-14
2024-06-30	$793,800	162,000	+1004.3%	Call	Sole	2024-08-14
2024-03-31	$105,183	14,670	—	Shares	Sole	2024-05-15
No filing history on record for this holder in this stock.